Greg Frank, the director of infectious disease policy at the Biotechnology Innovation Organization, said Achaogen’s fate sent a grave signal to companies in this space that are clamoring to prove their products’ success before cash runs out…
More from Morning Consult here.
Join senior editor Andrea Corona and Emily Wheeler, Director of Infectious Disease Policy at the Biotechnology Innovation Organization (BIO), as…
Read MoreMallory Smith was a young woman who, in her own words, had "big dreams and big goals." When she was…
Read MoreAntibiotics cannot cure COVID. They don’t help a bit. And yet, new data shows that, during the pandemic, COVID patients…
Read MoreThe push for antibiotics to fight fast-evolving superbugs is snagging on a broken business model. Six startups have won Food and Drug…
Read More